ArticleThe Journal of clinical investigation2017
Enterobacteria secrete an inhibitor of Pseudomonas virulence during clinical bacteriuria.
Article in The Journal of clinical investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Rewriting the urinary tract paradigm: the urobiome as a gatekeeper of host defense.Molecular biology reports · 2025Review
- Heterologous Expression of a Cryptic BGC fromACS synthetic biology · 2025Article
- Urinary Tract Infections Detection with Molecular Biomarkers.Biomolecules · 2024Review
- Article
- Uropathogenic Escherichia coli wield enterobactin-derived catabolites as siderophores.The Journal of biological chemistry · 2024Article
- UropathogenicbioRxiv : the preprint server for biology · 2023Article
- Competitive Inoculation as an Effective Prophylaxis Against Recurrent Urinary Tract Infections: A Systematic Review.International neurourology journal · 2023Article
- E. coli catheter-associated urinary tract infections are associated with distinctive virulence and biofilm gene determinants.JCI insight · 2023Article
- Two new siderophores produced byFrontiers in microbiology · 2023Article
- ThemBio · 2022Article
- Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects.Research and reports in urology · 2022Review
- Iron Transport and Metabolism in Escherichia, Shigella, and Salmonella.EcoSal Plus · 2021Article
- Pyochelin Biosynthetic Metabolites Bind Iron and Promote Growth inACS infectious diseases · 2021Article
- Iron Acquisition by Bacterial Pathogens: Beyond Tris-Catecholate Complexes.Chembiochem : a European journal of chemical biology · 2020Review
- Metabolomics Study on Pathogenic and Non-pathogenicMetabolites · 2020Article
- Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies.Nature reviews. Microbiology · 2020Review
- A Rare Opportunist,Infection and immunity · 2019Article
- Yersiniabactin-Producing Adherent/Invasive Escherichia coli Promotes Inflammation-Associated Fibrosis in GnotobioticInfection and immunity · 2019Article
- The Bladder is Not Sterile: an Update on the Urinary Microbiome.Current bladder dysfunction reports · 2019Article
- YbtT is a low-specificity type II thioesterase that maintains production of the metallophore yersiniabactin in pathogenic enterobacteria.The Journal of biological chemistry · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Escherichia coli and other Enterobacteriaceae are among the most common pathogens of the human urinary tract. Among the genetic gains of function associated with urinary E. coli isolates is the Yersinia high pathogenicity island (HPI), which directs the biosynthesis of yersiniabactin (Ybt), a virulence-associated metallophore. Using a metabolomics approach, we found that E. coli and other Enterobacteriaceae expressing the Yersinia HPI also secrete escherichelin, a second metallophore whose chemical structure matches a known synthetic inhibitor of the virulence-associated pyochelin siderophore system in Pseudomonas aeruginosa. We detected escherichelin during clinical E. coli urinary tract infection (UTI) and experimental human colonization with a commensal, potentially probiotic E. coli bacteriuria strain. Escherichelin production by colonizing enterobacteria may help human hosts resist opportunistic infections by Pseudomonas and other pyochelin-expressing bacteria. This siderophore-based mechanism of microbial antagonism may be one of many elements contributing to the protective effects of the human microbiome. Future UTI-preventive probiotic strains may benefit by retaining the escherichelin biosynthetic capacity of the Yersinia HPI while eliminating the Ybt biosynthetic capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.